Free Trial

Illumina (ILMN) Stock Price, News & Analysis

-1.54 (-1.43%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
1.69 million shs
Average Volume
1.72 million shs
Market Capitalization
$16.86 billion
P/E Ratio
Dividend Yield
Price Target

Illumina MarketRank™ Stock Analysis

Analyst Rating
2.30 Rating Score
55.6% Upside
$164.65 Price Target
Short Interest
2.99% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.08mentions of Illumina in the last 14 days
Based on 8 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.87 to $2.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

38th out of 915 stocks

Analytical Instruments Industry

1st out of 28 stocks

ILMN stock logo

About Illumina Stock (NASDAQ:ILMN)

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

ILMN Stock Price History

ILMN Stock News Headlines

ILMN Jun 2024 130.000 call
Anna Richo joins Illumina's Board of Directors
GRAIL to Host Capital Markets Day
Illumina: Expect A Slow Rebound
Beyond The Numbers: 6 Analysts Discuss Illumina Stock
Illumina Inc. Q1 Earnings Summary
See More Headlines
Receive ILMN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Illumina and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Life Sciences Tools & Services
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
20 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$4.50 billion
Cash Flow
$3.52 per share
Book Value
$35.99 per share


Free Float
Market Cap
$16.86 billion

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Jacob Thaysen Ph.D. (Age 49)
    CEO & Director
    Comp: $796.63k
  • Ms. Carissa L. Rollins (Age 54)
    Chief Information Officer
    Comp: $693.52k
  • Mr. Charles E. Dadswell Esq. (Age 65)
    Senior VP & General Counsel
    Comp: $1.03M
  • Dr. Joydeep Goswami M.B.A. (Age 53)
    Ph.D., Advisor
    Comp: $843.55k
  • Stephanie Campos
  • Mr. Ankur Dhingra (Age 48)
    Chief Financial Officer
  • Mr. Kevin Carl Pegels (Age 56)
    Chief of Global Operations
  • Mr. Scott Ericksen (Age 51)
    VP & Chief Accounting Officer
  • Dr. Steven Barnard Ph.D.
    Chief Technology Officer
  • Ms. Sallilyn Schwartz
    Vice President of Investor Relations

ILMN Stock Analysis - Frequently Asked Questions

Should I buy or sell Illumina stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 10 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View ILMN analyst ratings
or view top-rated stocks.

What is Illumina's stock price target for 2024?

20 analysts have issued 12-month price targets for Illumina's stock. Their ILMN share price targets range from $100.00 to $253.00. On average, they expect the company's stock price to reach $164.65 in the next twelve months. This suggests a possible upside of 55.6% from the stock's current price.
View analysts price targets for ILMN
or view top-rated stocks among Wall Street analysts.

How have ILMN shares performed in 2024?

Illumina's stock was trading at $139.24 at the beginning of 2024. Since then, ILMN stock has decreased by 24.0% and is now trading at $105.85.
View the best growth stocks for 2024 here

When is Illumina's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our ILMN earnings forecast

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) posted its earnings results on Thursday, May, 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The life sciences company had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.05 billion. Illumina had a positive trailing twelve-month return on equity of 2.31% and a negative net margin of 28.71%. Illumina's revenue was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.08 earnings per share.
Read the conference call transcript

What guidance has Illumina issued on next quarter's earnings?

Illumina updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.4 billion-$4.4 billion, compared to the consensus revenue estimate of $4.5 billion.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina Chief Executive Officer Francis deSouza on Francis deSouza has an approval rating of 92% among the company's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), Walt Disney (DIS), PayPal (PYPL), Salesforce (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's major shareholders?

Illumina's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.45%), Baillie Gifford & Co. (3.60%), Janus Henderson Group PLC (2.31%), WCM Investment Management LLC (2.12%), Bank of New York Mellon Corp (1.78%) and Capital World Investors (1.73%). Insiders that own company stock include Aimee L Hoyt, Alexander Aravanis, Charles Dadswell, Jacob Thaysen, Phillip G Febbo, Susan H Tousi and Susan H Tousi.
View institutional ownership trends

How do I buy shares of Illumina?

Shares of ILMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Illumina have any subsidiaries?
The following companies are subsidiares of Illumina: Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueBee Belgium BVBA, BlueBee Holding BV, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Emedgene Inc., Emedgene Technologies Ltd, Enancio, Enancio SAS, Epicentre Biotechnologies, GRAIL LLC, GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada ULC, Illumina Denmark ApS, Illumina Finland Oy, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus LLC, Illumina Shanghai (Trading) Co Ltd Beijing Branch, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Software Inc., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., Liquid Logic, Moleculo, NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.
Read More
This page (NASDAQ:ILMN) was last updated on 5/24/2024 by Staff

From Our Partners